Harpoon Therapeutics Inc
NASDAQ:HARP
Intrinsic Value
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. [ Read More ]
The intrinsic value of one HARP stock under the Base Case scenario is 11.25 USD. Compared to the current market price of 23.01 USD, Harpoon Therapeutics Inc is Overvalued by 51%.
Valuation Backtest
Harpoon Therapeutics Inc
Run backtest to discover the historical profit from buying and selling HARP stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Harpoon Therapeutics Inc
Current Assets | 34.3m |
Cash & Short-Term Investments | 31.6m |
Other Current Assets | 2.7m |
Non-Current Assets | 13.3m |
PP&E | 12.4m |
Other Non-Current Assets | 900k |
Current Liabilities | 18.1m |
Accounts Payable | 3.4m |
Accrued Liabilities | 14.7m |
Non-Current Liabilities | 24.9m |
Long-Term Debt | 8.8m |
Other Non-Current Liabilities | 16.1m |
Earnings Waterfall
Harpoon Therapeutics Inc
Revenue
|
37.3m
USD
|
Operating Expenses
|
-74.7m
USD
|
Operating Income
|
-37.4m
USD
|
Other Expenses
|
6.9m
USD
|
Net Income
|
-30.5m
USD
|
Free Cash Flow Analysis
Harpoon Therapeutics Inc
What is Free Cash Flow?
HARP Profitability Score
Profitability Due Diligence
Harpoon Therapeutics Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Harpoon Therapeutics Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
HARP Solvency Score
Solvency Due Diligence
Harpoon Therapeutics Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Harpoon Therapeutics Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HARP Price Targets Summary
Harpoon Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for HARP is 24.14 USD with a low forecast of 23.23 USD and a high forecast of 28.35 USD.
Ownership
HARP Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
HARP Price
Harpoon Therapeutics Inc
Average Annual Return | -21.96% |
Standard Deviation of Annual Returns | 62.51% |
Max Drawdown | -99% |
Market Capitalization | 492.3m USD |
Shares Outstanding | 21 397 200 |
Percentage of Shares Shorted | 3.24% |
HARP News
Last Important Events
Harpoon Therapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Harpoon Therapeutics Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. The company is headquartered in South San Francisco, California and currently employs 99 full-time employees. The company went IPO on 2019-02-08. The firm is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The company is developing a pipeline of T cell engagers using its TriTACs, focused on the treatment of solid tumors and hematologic malignancies. The company has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN328, HPN217 and HPN536. The Company’s ProTriTAC product candidate include HPN601. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells.
Contact
IPO
Employees
Officers
The intrinsic value of one HARP stock under the Base Case scenario is 11.25 USD.
Compared to the current market price of 23.01 USD, Harpoon Therapeutics Inc is Overvalued by 51%.